Telix Pharmaceuticals Limited Stock
Stocks
TLX
AU000000TLX2
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Australian S.E.
04:10:05 17/11/26 pm AEDT
|
5-day change | 1st Jan Change | ||
| 13.33 AUD | -0.45% |
|
-3.41% | +19.02% |
| 10/11 | Telix Pharmaceuticals Limited - Analyst/Investor Day | |
| 05/11 | Telix Pharmaceuticals Limited Joins Thera4Care to Accelerate Translation of Next Generation FAP-Targeting Theranostics | CI |
| Market Cap | 4.55B 3.07B 2.79B 2.58B 2.33B 4.4B 288B 31.01B 12.29B 155B 11.53B 11.28B 490B | P/E 2026 * |
200x | P/E 2027 * | 2,313x |
|---|---|---|---|---|---|
| Enterprise Value | 5.06B 3.42B 3.1B 2.87B 2.59B 4.89B 321B 34.48B 13.66B 172B 12.82B 12.55B 545B | EV / Sales 2026 * |
3.62x | EV / Sales 2027 * | 3.12x |
| Free-Float |
84.31% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| TLX | Delayed | |
| TLPPF | Delayed | ||
| T3X | Real-time | ||
| T3X | Real-time | ||
| T3X | Delayed | ||
| T3X | Delayed |
Last Transcript: Telix Pharmaceuticals Limited
| 1 day | -0.45% | ||
| 1 week | -3.41% | ||
| Current month | +1.52% | ||
| 1 month | -13.44% | ||
| 3 months | -18.97% | ||
| 6 months | -6.52% | ||
| Current year | +19.02% |
| 1 week | 13.04 | 14.35 | |
| 1 month | 12.61 | 16.25 | |
| Current year | 8.26 | 18.22 | |
| 1 year | 8.26 | 18.22 | |
| 3 years | 8.26 | 31.97 | |
| 5 years | 3.55 | 31.97 | |
| 10 years | 0.46 | 31.97 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 03/01/2017 | |
Darren Smith
DFI | Director of Finance/CFO | 61 | 31/07/2022 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 51 | 03/01/2017 | |
Mark Nelson
CHM | Chairman | 66 | 03/02/2026 |
Jann Skinner
BRD | Director/Board Member | 68 | 19/06/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 30/10/26 | Buy | Director | 9,000 | 0.0026% | ||
| 29/10/26 | Free | Director | 1,095 | 0.0003% | ||
| 27/10/26 | Buy | Director | 7,812 | 0.0023% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.45% | -3.41% | -6.13% | +41.96% | 3.07B | ||
| -1.29% | -3.91% | +51.98% | +69.06% | 65.56B | ||
| -2.28% | -0.76% | +8.23% | +89.61% | 60.41B | ||
| -0.51% | +0.91% | +23.66% | +87.89% | 55.76B | ||
| -1.26% | -1.45% | +12.43% | +117.42% | 46.98B | ||
| -0.15% | -5.06% | +20.00% | +29.27% | 43.63B | ||
| -3.15% | -16.63% | +146.30% | +685.27% | 36.09B | ||
| +0.23% | +2.14% | +14.85% | +46.22% | 36.7B | ||
| -1.03% | -2.18% | +77.32% | +58.01% | 32.9B | ||
| +1.42% | +5.84% | -36.40% | +402.78% | 26.96B | ||
| Average | -0.86% | -1.86% | +31.22% | +162.75% | 41B | |
| Weighted average by Cap. | -1.04% | -1.60% | +34.43% | +149.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.4B 945M 858M 793M 716M 1.35B 88.7B 9.54B 3.78B 47.6B 3.54B 3.47B 151B | 1.59B 1.08B 977M 902M 815M 1.54B 101B 10.85B 4.3B 54.17B 4.03B 3.95B 172B |
| Net income | 27.07M 18.28M 16.61M 15.34M 13.86M 26.15M 1.72B 185M 73.11M 921M 68.59M 67.13M 2.92B | 2.65M 1.79M 1.62M 1.5M 1.36M 2.56M 168M 18.04M 7.15M 90.05M 6.71M 6.56M 285M |
| Net Debt | 510M 345M 313M 289M 261M 493M 32.35B 3.48B 1.38B 17.36B 1.29B 1.27B 54.99B | 426M 288M 261M 242M 218M 412M 27.02B 2.91B 1.15B 14.5B 1.08B 1.06B 45.93B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/11/26 | $13.33 | -0.45% | 1,428,926 |
| 16/11/26 | $13.39 | -1.40% | 1,105,902 |
| 13/11/26 | $13.58 | -0.88% | 877,947 |
| 12/11/26 | $13.70 | -2.28% | 2,345,160 |
| 11/11/26 | $14.02 | +1.59% | 1,993,317 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TLX Stock
Select your edition
All financial news and data tailored to specific country editions
















